CEL-SCI Corp filed an 8-K reporting a partnership with Dallah Pharma for the commercialization of Multikine in Saudi Arabia, with a Breakthrough Medicine Designation application submitted on August 22, 2025. A final agreement is expected in Q3 2025, enhancing patient access and sales potential.